Biomarin Pharmaceutical Q4 Earnings Outlook

Don't be caught off-guard: Biomarin Pharmaceutical BMRN releases its next round of earnings Thursday.

Want to skip the homework and get all the facts in one place? We thought so. Here is your everything-that-matters guide for today's Q4 earnings announcement after the bell.

Earnings and Revenue

Biomarin Pharmaceutical EPS is expected to be at a loss of 24 cents, according to sell-side analysts. Sales will likely be near $357.49 million.

In the same quarter last year, Biomarin Pharmaceutical posted a loss of 53 cents per share on sales of $300 million. If the company were to match the consensus estimate, earnings would be down 54.72 percent. Revenue would be up 19.13 percent from the year-ago period.

Here's how the company's EPS has stacked up against analyst estimates in the past:

Stock Performance

Over the last 52-week period, shares are down 6.7 percent. Given that these returns are generally negative, long-term shareholders are probably a little upset going into this earnings release.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. Analysts have been rating Biomarin Pharmaceutical stock as Neutral. The strength of this rating has maintained conviction over the past three months.

Conference Call

Don't be surprised to see the stock move on comments made during its conference call. Biomarin Pharmaceutical's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here: http://investors.biomarin.com/events-presentations